SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Olsson Erik 1956 )
 

Sökning: WFRF:(Olsson Erik 1956 ) > Randomized evaluati...

Randomized evaluation of routine beta-blocker therapy after myocardial infarction quality of life (RQoL) : design and rationale of a multicentre, prospective, randomized, open, blinded endpoint study

Humphries, Sophia (författare)
Karolinska Institutet,Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, 23100, Karolinska Institute , 141 83 Huddinge , Sweden
Mars, Katarina (författare)
Karolinska Institutet,Department of Clinical Science and Education, Division of Cardiology, Karolinska Institute , Stockholm , Sweden
Hofmann, Robin (författare)
Karolinska Institutet,Department of Clinical Science and Education, Division of Cardiology, Karolinska Institute , Stockholm , Sweden
visa fler...
Held, Claes, 1956- (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Olsson, Erik, 1967- (författare)
Uppsala universitet,Hälsovetenskap och e-hälsa
visa färre...
 (creator_code:org_t)
Oxford University Press, 2023
2023
Engelska.
Ingår i: European Heart Journal Open. - : Oxford University Press. - 2752-4191. ; 3:3
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • AimsMost cases of acute myocardial infarction (MI) in Sweden are treated with long-term β-blocker therapy as secondary prevention. Case studies and patient reports have indicated negative effects of β-blockers including symptoms of depression, fatigue, sexual dysfunction, and general low mood, all related to reduced quality of life (QoL). To date, no recent large-scale, randomized trial has explored the effects of β-blockers on these factors.Methods and resultsThe ongoing Randomized Evaluation of Decreased Usage of beta-bloCkErs after myocardial infarction (REDUCE): quality of life (RQoL) study is a multicentre, prospective, randomized pre-specified substudy aiming to evaluate the effects of β-blockers on self-reported measures of QoL. Following randomized allocation to long-term β-blocker or no β-blocker treatment, patients complete a total of six baseline measures pertaining to QoL, sexual functioning, and perceived side effects. Data collection is optionally carried out online through a unique and secure portal and repeated again at two follow-up time points. Recruitment began in July 2018. Data from the first 100 patients showed that at the first follow-up, 93% had completed the questionnaires, which decreased to 81% at the second follow-up. The method of digital data collection was utilized by over half of the patients recruited so far.ConclusionData from the first 100 patients indicate success in terms of study design and recruitment. The RQoL substudy investigates the effects of β-blockers on self-reported measures of QoL in MI patients and will potentially contribute to the limited knowledge of QoL-related side effects reported in conjunction with β-blocker use.Clinical trial registrationEudra CT number, 2017-002336-17; Clinical trial.gov identifier, NCT03278509

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy